| Literature DB >> 15823959 |
Richard H Weisbart1, James E Hansen, Robert N Nishimura, Grace Chan, Rika Wakelin, Sophia S Chang, Larry Baresi, Jeffrey S Chamberlain.
Abstract
The Fv fragment of an antibody that selectively targets and penetrates skeletal muscle in vivo was produced as a fusion protein with a micro-dystrophin for use as a delivery vehicle to transport micro-dystrophin into muscle cells. Fv-micro-dystrophin was produced as a secreted protein by transient transfection of Fv-micro-dystrophin cDNA in COS-7 cells and as a non-secreted protein by permanent transfection in Pichia pastoris. Isolated Fv-micro-dystrophin was shown to be full-length by Western blot analysis. Fv-micro-dystrophin penetrated multiple cell lines in vitro, and it localized to the plasma membrane of a cell line with membrane beta-dystroglycan. In the absence of membrane beta-dystroglycan, it localized to the cytoplasm. Antibody-mediated transduction of micro-dystrophin into muscle cells is a potential therapy for dystrophin-deficient muscular dystrophies.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15823959 DOI: 10.1080/10611860400029002
Source DB: PubMed Journal: J Drug Target ISSN: 1026-7158 Impact factor: 5.121